Download

 

Type: Case report
Published: 1-03-2018

 

Local reaction to FLEXHD® acellular dermal matrix in breast reconstruction: a case report and review of the literature

Robert Phan MBBS BBiomedSci PGDipSurgAnat,1 Frank Lin MBBS FRACS,1 Dean White MBBS GradDipBioEpi FRACS1

1

Department of Surgery
Faculty of Medicine
Monash University
Clayton, Victoria
AUSTRALIA

 

OPEN ACCESS

Correspondence

Name: Robert Phan

Address: Department of Surgery
Faculty of Medicine
Monash University
Wellington Road
Clayton, Victoria 3800
AUSTRALIA

Email: robert_phan@hotmail.com

Phone: +61 (0)3 9554 1000

Citation: Phan R, Lin F, White D. Local reaction to FlexHD® acellular dermal matrix in breast reconstruction: a case report and review of the literature. Aust J Plast Surg. 2018; 1(1): 142–148.https://doi.org/10.34239/ajops.v1i1.6

Accepted for publication: 8 December 2017

Copyright © 2018. Authors retain their copyright in the article. This is an open access article distributed under the Creative Commons Attribution Licence which permits unrestricted use, distribution and reproduction in any medium, provided the original work is properly cited.


Abstract

Introduction: Since its first reported use for the treatment of burns victims, acellular dermal matrix (ADM) use has expanded to surgeries including repairing thoracic and abdominal wall defects, and breast reconstruction. FlexHD® is a brand of ADM prepared from human cadaveric dermis that has been processed to remove antigenic components and is used to reinforce the subpectoral pocket created during submuscular breast implant surgery. Recent documentation of a phenomenon termed ‘red breast syndrome’ (RBS) has emerged in the medical literature, with little known about its aetiology and treatment. This paper presents a case of blistering cutaneous erythema from FlexHD® ADM, reviews the current literature on RBS and proposes a treatment methodology.

Case presentation: A 43-year-old woman presented with a self-detected right breast lump, which on biopsy was confirmed as grade I invasive ductal carcinoma. The patient subsequently underwent a right skin-sparing mastectomy and tissue expander insertion with FlexHD® ADM used to reinforce the submuscular pocket. On day seven post-operation, she developed a cutaneous erythema over the ADM associated with fevers and leukocytosis and was readmitted. She developed blistering over the erythema that worsened despite antibiotic and steroid therapy and was subsequently operated on to remove the ADM. Post-operatively, the erythema resolved.

Conclusion: Little is known about RBS, its aetiology and treatment, with emerging evidence of heterogeneous presentation beyond simply cutaneous erythema. RBS should be a diagnosis of exclusion but considered if cutaneous erythema is present and resistant to antibiotic therapy.

Key words: acellular dermis, breast implants, FlexHD, masectomy, erythema


Introduction

FlexHD® acellular dermal matrix (ADM) is a tissue matrix derived from human dermis that has been processed to remove cellular components that may trigger an immune or inflammatory response.1,2 It is one of many types of ADM present on the market, others being derived from porcine dermis or bovine tissue.2 First described as tissue replacement for burns victims in 1995 by Wainwright,3 the use of ADMs has expanded rapidly to areas of surgery including thoracic, abdominal wall and pelvic reconstruction, head, neck and breast reconstruction.

Despite widespread use of ADMs, with the 2016 Plastic Surgery Statistic Report quoting 53 per cent4 of all reported plastic reconstructive breast procedures in the United States incorporating ADM use, a recent systematic review by Blazeby et al5 was unable to find high quality evidence to demonstrate its impact on outcomes in immediate breast reconstruction, quoting lack of robust study designs and long-term follow up. Complication rates associated with FlexHD® are reported at 16.5 per cent, similar to AlloDerm,6 which includes soft tissue infection, flap necrosis, seroma and implant exposure.

Within the last five years, a new phenomenon termed ‘red breast syndrome’ (RBS) has emerged. It is poorly understood but is associated with the use of ADM in breast reconstruction, presenting as cutaneous erythema over the breast without systemic signs of infection. We present a case of RBS in a patient who had FlexHD® inserted, presenting with cutaneous erythema, but with associated blistering, and review the current literature on this phenomenon.

Case report

A 43-year-old woman presents with a self-detected right breast lump. The patient has previously had knee surgery, is a non-smoker, and has given birth to two children. She currently works as a physical education teacher, and is otherwise fit and healthy.

Core biopsies of right breast tissue prior to surgery confirmed grade I invasive ductal carcinoma, oestrogen and progesterone receptor positive and HER2 negative. The patient underwent a skin sparing right mastectomy, right axillary node dissection and tissue expander (TE) insertion with FlexHD®. A submuscular approach to TE insertion was performed underneath pectoralis major and serratus fascia with a 6 cm x 16 cm sheet of pliable FlexHD® used to cover the exposed lower pole of the TE, sutured on the superior aspect to pectoralis major and inferiorly to the level of inframammary fold using Vicryl, with two drain tubes inserted. The patient was administered perioperative cefazolin antibiotic which continued during her admission. The drain tubes were removed on the third post-operative day, and the patient was discharged home with cephalexin.

On day seven post operation, the patient noted warmth, erythema (Figure 1), swelling and itchiness around the lower pole of her right breast, specifically in the skin directly overlying the ADM, and was readmitted.

The patient’s temperature was 37.4C, with a white cell count of 11.5 x 109 cells/L (normal range 4.0–1.0) and CRP of 45 mg/L (normal range <5). She commenced on IV Flucloxacillin for presumed infection. On the third day of admission, blistering was noted at the inferior pole of the right breast directly overlying and in the shape of the inserted FlexHD® ADM (Figure 2).

An ultrasound scan of the breast was performed, with no collection or abscess present, with a very small amount of fluid surrounding the TE. A swab of the blister showed presence of white cells, but no organisms were cultured. Antibiotics were changed to Tazocin and intravenous hydrocortisone began. On the subsequent day she was taken to theatre for washout and removal of the ADM with preservation of the TE due to increased blistering with skin integrity in question, despite the patient being on Tazocin and hydrocortisone. Intraoperative findings were turbid fluid but no pus around the TE. Tissue, swabs of fluid and the FlexHD® (Figure 3) were sent off for histopathology, microscopy and culture. The sub-pectoral pocket was washed out with sterile saline, with 50cc of fluid removed from the TE.

Hydrocortisone ceased on the first postoperative day, and vancomycin commenced in conjunction with Tazocin. Within twenty-four hours, the area showed improvement with significantly less redness noted, and her antibiotics were changed to oral Flucloxacillin on the fifth postoperative day. She was discharged home on the seventh postoperative day with four weeks of Flucloxacillin to cover the possibility of infection. Cultures of right breast fluid, blister fluid, capsule and surrounding breast tissue were negative, with occasional leukocytes seen on microscopy. Histopathology of ADM demonstrated strips of dense fibroadipose tissue with neutrophilic infiltrate, with irregular cystic spaces present and with no granulomas identified (Figure 4), suggestive of abscess formation reaction against foreign material. On her one-month review, the patient’s symptoms had completely resolved. The patient has since undergone a TE to implant exchange on the right breast, with implant inserted on the contralateral side (Figure 5).

Fig. 1 Cutaneous erythema present at lower pole of breast overlying FlexHD® ADM.

Fig. 2 Blistering over region of cutaneous erythema overlying FlexHD® ADM.

Fig. 3 Tissue specimen of FlexHD® ADM removed from patient.

Fig. 4 Histopathology of FlexHD® ADM demonstrating neutrophilic infiltrate together with irregular cystic space.

Fig. 5 Post-operative follow-up after exchange of right breast tissue expander implant.

 

Discussion

Since the first documented use of ADM for breast reconstruction in the scientific literature by Breuing and Warren7 in 2005, the use of ADMs in immediate breast reconstruction has increased significantly, with a recent survey quoting 84 per cent of plastic surgeon respondents routinely using ADM in breast reconstruction8 and multiple authors reporting favourable outcomes.6 Acellular dermal matrix is sutured between the lower border of pectoralis muscle and chest wall, creating a lower-pole sling where a defect would normally exist. This theoretically allows both for greater intraoperative filling of TE and reduced time until expansion is complete, and, in some cases where appropriate, a single-stage procedure due to the reinforced subpectoral pocket allowing for immediate insertion of implant.5

‘Red breast syndrome’ was first documented in 20099 after the authors of a study into AlloDerm ADM noted some patients developed a non-infectious erythema that mimicked cellulitis present at the lower mastectomy skin flap overlying the ADM without local signs of infection. In these cases, the erythema noted was refractory to antibiotic therapy and self-limiting, hypothesised to be an inflammatory response to the preservatives in which AlloDerm was packaged.9 Newman et al10 noted similar findings in relation to AlloDerm, reporting there was no pain, elevated skin temperature or induration present. However, the authors reported that there was no elevations of serum markers such as white blood cell count and C-reactive protein, contrary to our findings, and that if left untreated, was self-limiting and self-resolving. Since this first documentation in the literature of an erythematous reaction, further cases have been reported, although variable in terms of period of onset after ADM insertion, associated symptoms and treatment methodologies.

Presentation

Multiple case reports and series9,11–13 have identified RBS as characterized by a cutaneous erythema localized to skin overlying an ADM, with some reports14 quoting an incidence of up to 7.6 per cent. Most studies so far have mentioned RBS in passing, without clear case presentation and analysis. Slavin et al11 reported a case series of four patients who had an ADM inserted presenting with breast erythema resistant to antibiotics; some presenting with symptoms of erythema, and systemic symptoms of fevers, chills and night sweats associated with breast erythema that manifested up to nine months after the initial operation. Kim et al6 also noted similar clinical findings, further reporting an absence of objective signs of infection such as fever and leukocytosis, and no radiographic evidence of seroma or abscess. Their findings contrast with our own, which found leukocytosis along with the development of an aseptic abscess from foreign body reaction and hence the presence or absence of leukocytosis and radiologic findings should not necessarily pre-clude a diagnosis of RBS.

In recent literature, and from our case presented, there is emerging evidence of heterogeneity in RBS presentations beyond just cutaneous erythema. A report by Saunders et al12 found pustular dermatitis overlying erythema present on the lower pole of the breast that had FlexHD® inserted and which failed to respond to antibiotic therapy.

Summary of features of RBS

Clinical Signs and Symptoms

Must be present
  • Stable cutaneous erythema: Note: May be associated with other phenomenon e.g. blistering, pustules
  • Patient systemically well
Variable in presentation
  • Itch
  • Rash
  • Warmth around ADM site
  • Fever and chills
  • Resolution of erythema

Aetiology

Multiple theories as to why RBS develops have been put forward. Kim et al15 reported a case of incorrect ADM insertion leading to an erythematous cutaneous breast that required removal of the ADM; ADM exhibits polarity, and must be inserted with the fenestrated (dermal) surface opposing soft tissue and the smooth surface facing the TE or implant. The authors postulate the possibility of the incorporation of the graft being compromised by incorrect insertion leading to lack of proper tissue ingrowth and revascularization, in turn leading to the host immune system identifying the ADM as foreign and subsequently the development of a foreign body reaction.

The possibility of incorrect preparation of ADM was also explored, with Kim et al13 reporting sterile AlloDerm preparation being associated with a clinically, but not statistically, decreased incidence of seroma, necrosis and RBS compared to aseptic ADM preparation. Those with presumed RBS were treated empirically for possible cellulitis, with the erythema resolving over several weeks in all patients.

An earlier review by Jacobson et al16 noted unilateral RBS in some of the authors’ patients who underwent bilateral reconstruction with ADM. The reason for this peculiarity is uncertain, as preparation of the ADM and its insertion should be very similar, if not identical, as performed by the same surgeon for the same patient. Unless the chemical constituents of the ADM used were highly variable between the same product, which seems unlikely, the more plausible explanation is that the current methods of manufacture of ADM does not eliminate all cellular antigenic products, which some manufacturers have alluded to.2

All cases of RBS share the common phenomenon of symptoms presenting from a week to months after initial ADM insertion. The delayed presentation of documented cases of RBS, and cell infiltrate found in the biopsy, combined with resolution from using corticosteroids—a known im-munosuppressive agent—suggests a likely immunological component, as reported by Slavin et al11 in a four-case series where immune-suppressant medication resolved the symptoms. The delayed presentation of RBS suggests a type IV T cell-mediated hypersensitivity reaction, similar to diseases including type I diabetes and multiple sclerosis, brought on by activated T cell lymphocytes.17 However, this reaction usually occurs due to prior sensitisation to a specific antigen, possibly due to inadequate preparation of the ADM or inadvertent impregnation of antigens into the ADM in theatre during preparations for insertion. In this case, the histopathology report noted a sterile foreign body reaction consistent with the hypothesis of delayed hypersensitivity.

Similar cutaneous erythematous events have occurred during breast reconstructions without the use of ADM, which some have attributed to lymphatic obstruction,18 while others19 have documented as a ‘delayed breast cellulitis’ mimicking symptoms of RBS. Delayed breast cellulitis, occurring on dependent breast portions around and below the nipple and areola region and reported as being resistant to antibiotics, improved after the patient changed to a supine position, and was self-resolving. It is possible that RBS is delayed breast cellulitis that is now being noticed in patients with ADM inserted, however with the current, minimal number of histopathological studies available on either phenomenon, such a distinction cannot be made.

Treatment

Due to the lack of reporting and understanding of RBS, there is currently no recognised treatment regime. The heterogeneous presentations of RBS also suggest that it is likely a condition with multiple causes but which present in a similar manner, making it difficult to distinguish from one case to another and to treat appropriately. However, the presentations of erythema can be associated with severe outcomes depending on cause, and hence RBS should be a diagnosis of exclusion, once other diagnosis have been ruled out.

If there are clear signs of cellulitis, including spreading cutaneous erythema associated with fever and leukocytosis, the patient should be treated for cellulitis as per empiric antibiotic therapy, with swabs of fluid for culture and sensitivities. Whether worsening cellulitis requires the removal of the ADM, despite antibiotic therapy, is dependent on the judgement of a surgeon.

Should antibiotic therapy fail, and the erythema is noted to be stable with the patient systemically well, a trial of corticosteroids may be considered. Commencing steroid therapy prior to antibiotic therapy is discouraged, as it transiently increases the white cell count—due to inhibition of white cell adhesion to endothelial cells for migration into tissue—hence reducing the immunological response.17

The question of ADM removal in RBS is patient and surgeon dependent. Severe reactions or multiple episodes of RBS should warrant strong consideration of removal.

Fig. 6 Treatment algorithm when presented with cutaneous erythema after insertion of ADM

Conclusion

The aetiology, risk factors and treatment of RBS red breast syndrome are elusive. While the presentations of RBS can be varied, the current literature, as well as our case, demonstrate that RBS is primarily characterised by a cutaneous erythema over the region of an inserted ADM. The presence or absence of systemic symptoms should not be the primary determining factor in stratifying RBS from infection, but rather the presence or absence of stable erythema. Further recognition and study of this condition is required to determine cause and appropriate treatment.

Disclosure

The authors have no financial or commercial conflicts of interest to disclose.

References

  1. Discover your breast reconstruction options with mentor breast implants—brochure. [Cited 18 October 2016.] Available from URL: http://www.mentorwwllc.com/documents/0809009_recon.pdf
  2. Cheng A, Saint-Cyr M. Comparison of different ADM materials in breast surgery. Clin Plast Surg. 2012; 39(2): 167–75. https://doi.org/10.1016/j.cps.2012.02.004 PMid:22482358
  3. Wainwright DJ. Use of an acellular allograft dermal matrix (AlloDerm) in the management of full-thickness burns. Burns 1995; 21(4): 243–48. https://doi.org/10.1016/0305-4179(95)93866-I
  4. 2016 Plastic Surgery Statistics Report. American Society of Plastic Surgeons, 2016. [Cited 18 October 2016.] Available from URL: https://www.plasticsurgery.org/documents/News/Statistics/2016/plastic-surgery-statistics-full-report-2016.pdf
  5. Potter S, Browning D, Savovic J, Holcombe C, Blazeby JM. Systematic review and critical appraisal of the impact of acellular dermal matrix use on the outcomes of implant-based breast reconstruction. Br J Surg. 2015; 102(9): 1010–025. https://doi.org/10.1002/bjs.9804 PMid:26109277
  6. Rawlani V, Buck DW, Johnson SA, Heyer KS, Kim JY. Tissue expander breast reconstruction using prehydrated human acellular dermis. Ann Plast Surg. 2011; 66(6): 593–97. https://doi.org/10.1097/SAP.0b013e3181f3ed0a PMid:21233698
  7. Breuing KH, Warren SM. Immediate bilateral breast reconstruction with implants and inferolateral AlloDerm slings. Ann Plast Surg. 2005; 55(3): 232–39. https://doi.org/10.1097/01.sap.0000168527.52472.3c
  8. Ibrahim AM, Koolen PG, Ashraf AA, Kim K, Mureau MA, Lee BT, Lin SJ. Acellular dermal matrix in reconstructive breast surgery: survey of current practice among plastic surgeons. Plast Reconstr Surg Glob Open. 2015: 1–8. https://doi.org/10.1097/GOX.0000000000000148
  9. Nahabedian MY. AlloDerm performance in the setting of prosthetic breast surgery, infection, and irradiation. Plast Reconstr Surg. 2009; 124(6): 1743–753. https://doi.org/10.1097/PRS.0b013e3181bf8087 PMid:19952629
  10. Newman MI, Hanabergh E, Samson MC. AlloDerm performance in the setting of prosthetic breast surgery, infection, and irradiation. Plast Reconstr Surg. 2010; 126(3): 1120. https://doi.org/10.1097/PRS.0b013e3181e60652 PMid:20811254
  11. Ganske I, Hoyler M, Fox SE, Morris DJ, Lin SJ, Slavin SA. Delayed hypersensitivity reaction to acellular dermal matrix in breast reconstruction: the red breast syndrome? Ann Plast Surg. 2014; 73 Suppl 2: S139–143. https://doi.org/10.1097/SAP.0000000000000130
  12. James J, Jackson L, Saunders C. Florid pustular dermatitis of breast: a case report on a unusual complication from acellular dermal matrix use. Int J Surg Case Rep. 2016; 22: 59–61. https://doi.org/10.1016/j.ijscr.2016.02.040 PMid:27058152 PMCid:PMC4832039
  13. Lewis P, Jewell J, Mattison G, Gupta S, Kim H. Reducing postoperative infections and red breast syndrome in patients with acellular dermal matrix-based breast reconstruction: the relative roles of product sterility and lower body mass index. Ann Plast Surg. 2015; 74 Suppl 1: S30–32. https://doi.org/10.1097/SAP.0000000000000475
  14. Hill JL, Wong L, Kemper P, Buseman J, Davenport DL, Vasconez HC. Infectious complications associated with the use of acellular dermal matrix in implant-based bilateral breast reconstruction. Ann Plast Surg. 2012; 68(5): 432–34. https://doi.org/10.1097/SAP.0b013e31823b6ac6 PMid:22531395
  15. Heyer K, Buck DW, Kato C, Khan SA, Alam M, Kim JYS. Reversed acellular dermis: failure of graft incorporation in primary tissue expander breast reconstruction resulting in recurrent breast cellulitis. Plast Reconstr Surg. 2010; 125(2): 66e–68e. https://doi.org/10.1097/PRS.0b013e3181c7264e
  16. Wu PS, Winocour S, Jacobson SR. Red breast syndrome: a review of available literature. Aesthetic Plast Surg. 2015; 39(2): 227–30. https://doi.org/10.1007/s00266-014-0444-x PMid:25608912
  17. Kumar V, Abbas AK, Aster JC, Robbins SL. Robbins and Cotran. Pathologic basis of disease. Philadelphia: Elsevier-Saunders, 2015.
  18. Cichowitz A, Stanley PA, Morrison WA. Erysipelas-like inflammation following breast surgery. J Plast Reconstr Aesthetic Surg. 2007; 60(5): 490–94. https://doi.org/10.1016/j.bjps.2006.04.013 PMid:17399657
  19. Zippel D, Siegelmann-Danieli N, Ayalon S, Kaufman B, Pfeffer R, Zvi Papa M. Delayed breast cellulitis following breast conserving operation. Eur J Surg Oncol. 2003; 29(4): 327–30. https://doi.org/10.1053/ejso.2002.1377 PMid:12711284